[go: up one dir, main page]

DE69632967D1 - Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3) - Google Patents

Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3)

Info

Publication number
DE69632967D1
DE69632967D1 DE69632967T DE69632967T DE69632967D1 DE 69632967 D1 DE69632967 D1 DE 69632967D1 DE 69632967 T DE69632967 T DE 69632967T DE 69632967 T DE69632967 T DE 69632967T DE 69632967 D1 DE69632967 D1 DE 69632967D1
Authority
DE
Germany
Prior art keywords
repellation
lymphoycyte
transplants
lag
grass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69632967T
Other languages
English (en)
Other versions
DE69632967T2 (de
Inventor
Mauro Biffoni
Ruben Papoian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of DE69632967D1 publication Critical patent/DE69632967D1/de
Application granted granted Critical
Publication of DE69632967T2 publication Critical patent/DE69632967T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69632967T 1996-11-29 1996-11-29 Verfahren zur Verhinderung der Transplantabstoßung bei einer Transplantation und zur Herstellung einer universalen Gentherapie-Wirtszelle unter Anwendung von Lymphocyten-Aktivierungsgen (LAG-3) Expired - Fee Related DE69632967T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1996/005280 WO1998023748A1 (en) 1996-11-29 1996-11-29 Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)

Publications (2)

Publication Number Publication Date
DE69632967D1 true DE69632967D1 (de) 2004-08-26
DE69632967T2 DE69632967T2 (de) 2005-08-11

Family

ID=8166413

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69632967T Expired - Fee Related DE69632967T2 (de) 1996-11-29 1996-11-29 Verfahren zur Verhinderung der Transplantabstoßung bei einer Transplantation und zur Herstellung einer universalen Gentherapie-Wirtszelle unter Anwendung von Lymphocyten-Aktivierungsgen (LAG-3)

Country Status (20)

Country Link
US (1) US6500422B2 (de)
EP (1) EP0941329B1 (de)
JP (1) JP3920928B2 (de)
KR (1) KR100481230B1 (de)
AR (1) AR018489A1 (de)
AT (1) ATE271607T1 (de)
AU (1) AU733825B2 (de)
BR (1) BR9612821A (de)
CA (1) CA2272130C (de)
DE (1) DE69632967T2 (de)
DK (1) DK0941329T3 (de)
EA (1) EA003772B1 (de)
ES (1) ES2225901T3 (de)
HK (1) HK1023599A1 (de)
IL (1) IL130168A (de)
NO (1) NO324378B1 (de)
PT (1) PT941329E (de)
UA (1) UA73270C2 (de)
WO (1) WO1998023748A1 (de)
ZA (1) ZA9710737B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500422B2 (en) * 1996-11-29 2002-12-31 Applied Research Systems Ars Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3)
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
ES2947575T3 (es) 2013-09-20 2023-08-11 Bristol Myers Squibb Co Combinación de anticuerpos anti-LAG-3 y anticuerpos anti-PD-1 para tratar tumores
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
MA43576A (fr) 2015-12-16 2018-11-14 Merck Sharp & Dohme Anticorps anti-lag3 et fragments de fixation à l'antigène
CA3053357A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
EP4516809A2 (de) 2017-04-05 2025-03-05 F. Hoffmann-La Roche AG Bispezifische antikörper mit spezifischer bindung an pd1 und lag3
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
BR112019020610A2 (pt) 2017-05-30 2020-04-22 Bristol-Myers Squibb Company tratamento de tumores positivos para o lag-3

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
WO1995030750A2 (fr) 1994-05-06 1995-11-16 Institut Gustave Roussy Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
US6500422B2 (en) * 1996-11-29 2002-12-31 Applied Research Systems Ars Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3)

Also Published As

Publication number Publication date
US20020081282A1 (en) 2002-06-27
IL130168A0 (en) 2000-06-01
NO992569D0 (no) 1999-05-27
ATE271607T1 (de) 2004-08-15
NO324378B1 (no) 2007-10-01
NO992569L (no) 1999-05-27
AU1066797A (en) 1998-06-22
CA2272130C (en) 2007-10-23
IL130168A (en) 2006-09-05
US6500422B2 (en) 2002-12-31
EP0941329A1 (de) 1999-09-15
CA2272130A1 (en) 1998-06-04
JP3920928B2 (ja) 2007-05-30
EA003772B1 (ru) 2003-08-28
PT941329E (pt) 2004-11-30
ZA9710737B (en) 1998-07-30
AU733825B2 (en) 2001-05-24
EP0941329B1 (de) 2004-07-21
WO1998023748A1 (en) 1998-06-04
KR20000053291A (ko) 2000-08-25
JP2001505770A (ja) 2001-05-08
AR018489A1 (es) 2001-11-28
KR100481230B1 (ko) 2005-04-07
EA199900507A1 (ru) 2000-02-28
DE69632967T2 (de) 2005-08-11
HK1023599A1 (en) 2000-09-15
UA73270C2 (en) 2005-07-15
BR9612821A (pt) 2000-04-11
ES2225901T3 (es) 2005-03-16
DK0941329T3 (da) 2004-11-29

Similar Documents

Publication Publication Date Title
DE69632967D1 (de) Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3)
DE69113386D1 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
CA2293575A1 (en) Controlled release microencapsulated ngf formulation
DE60033051D1 (de) Methode und einrichtung zur kontinuierlichen herstellung von diarylcarbonaten
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU6968898A (en) Antisense oligonucleotide compositions and methods for the modulation of activating protein
DE69927388D1 (de) Gerät zur verabreichung von medikamenten und genen in gewebe
ID22349A (id) Turunan dari 8-azabisiklo [3.2.1] oktana-, 8-azabisiklo [3.2.1] okt-6-ena-, 9-azabisiklo-[3.3.1] nonana-, 9-aza-3-oksabisiklo [3.3.1] nonana- dan 9-aza-3-tiobisiklo [3.3.1] nonana, pembuatannya dan penggunaannya sebagai insektisida
DE69623587D1 (de) Vorrichtung zur Herstellung von Polstermaterial
DE69307733D1 (de) Calix-[4]-arene-bis-kronen, ihre herstellung und ihre anwendung zur selektiven extrahierung von cäsium und aktiniden
AU1798995A (en) Use of extracts of filamentous bacteria as cosmetic agents to combat ageing of the skin
DE59504187D1 (de) Verfahren zur Herstellung von ultrareinem Bisphenol-A und dessen Verwendung
DE3669507D1 (de) 1-benzyl-2-(n-substituierte)-carbamoyltetrahydroisochinoline und methode zur ihrer herstellung.
HUP9903249A3 (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DE69828191D1 (de) Verfahren zur herstellung von 2,6-dialkylnaphthalin
DE69522671D1 (de) Elektroaktiver Werkstoff, seine Herstellung und seine Verwendung zur Herstellung von kathodischen Elementen
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
DE69519602D1 (de) Kugelförmige Aktivkohle zur Behandlung von Hämorrhoiden
DE69713040D1 (de) Verfahren zur Herstellung von Cyclopropylacetylen und dessen Derivaten
NO992504D0 (no) Sammensetninger for behandling av jord, fremgangsmÕte for fremstilling derav, samt anvendelse
DE69724613D1 (de) Antimikrobielle Mittel gegen eukaryotische Mikroorganismen und Verfahren zur Unterdrückung des Wachstums von eukaryotischen Mikroorganismen unter Verwendung solcher Mittel
ATE321772T1 (de) Echinocandinderivate, deren herstellung und deren verwendung zur bekämpfung von pilzen
DE69823191D1 (de) 1,2,3-thiadiazol-derivate, mittel zur kontrolle von pflanzenkrankheiten und methode zu seiner anwendung
DE69701404D1 (de) Umesterungsverfahren zur Herstellung von Dihydromyrcenol und Myrcenol
DE69435058D1 (de) Vektor zur vielfachklonierung, expressionsvektor und herstellung von fremdprotein mit expressionsvektor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee